| Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study 2014 · treatment group · Adults with diverticulosis and at least one previous mild or moderate episode of diverticulitis requiring treatment; mean age 63.7 years, 17 women and 13 men among completers | 300 mg | 1 year | 37 |
| Butyrate improves handgrip strength and physical performance by reducing intestinal leak in post-menopausal women, a randomized controlled trial 2025 · butyrate · Post-menopausal women; mean age 54 ± 2.8 years | 570 mg | 12 weeks | 70 |
| Butyrate supplementation reduces sarcopenia by repairing neuromuscular junction in patients with chronic obstructive pulmonary disease 2024 · butyrate group · Patients with chronic obstructive pulmonary disease (age and sex not specified) | 300 mg | 12 weeks | 64 |
| Oral butyrate improves postural balance by repairing leaky gut in geriatric adults 2025 · butyrate group · geriatric adult men, age range 70.4 ± 2.9 years | 300 mg | 16 weeks | 64 |
| Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis: Results From a Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study 2025 · intervention group · Adults aged 18 years and older with mild-to-moderate active ulcerative colitis, receiving stable UC therapy | 600 mg | 8 weeks | 54 |
| Butyrate (short-chain fatty acid) alleviates lipopolysaccharide-binding proteins and improves physical function in knee osteoarthritis patients 2025 · butyrate group · Patients with knee osteoarthritis; age and sex not reported | 300 mg | 12 weeks | 52 |
| Colonic butyrate administration modulates fear memory but not the acute stress response in men: A randomized, triple-blind, placebo-controlled trial 2024 · butyrate group · healthy men, mean age 25.2 years | 5.28 g | 7 days | 35 |
| Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine 1999 · GHB group · Adults with alcohol withdrawal syndrome; mean age 41.7 years; 26 males and 4 females | 50 mg/kg | 10 days | 30 |
| Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial 2022 · butyrate group · Children aged 5–17 years with obesity (BMI greater than the 95th percentile for sex and age) | 20 mg/kg | 26 weeks | 27 |
| Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study 2000 · Group A · Patients with mild to moderate ulcerative colitis | 4 g | 6 weeks | 12 |
| Nutritional Management in Stricturing Crohn's Disease: A Pilot Study 2024 · Study group: diet plus EAA and sodium butyrate supplementation · Adults with stricturing Crohn’s disease | 400 mg | 1 year | 10 |
| Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial 2025 · calcium butyrate · Children aged 4–17 years with irritable bowel syndrome diagnosed according to Rome IV criteria | 500 mg | 8 weeks | 26 |
| Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study 2025 · PA + BA + placebo · Adults aged 18–90 with a diagnosed primary Parkinsonian syndrome and moderate disease severity | 2.4 g | 26 weeks | 24 |
| Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study 2025 · 2FL + PA + BA · Adults aged 18–90 with a diagnosed primary Parkinsonian syndrome and moderate disease severity | 2.4 g | 26 weeks | 24 |
| Effects of Oral Butyrate on Blood Pressure in Patients With Hypertension: A Randomized, Placebo-Controlled Trial 2024 · butyrate group · Dutch adults aged 40–65 with mild hypertension; men and postmenopausal women were eligible | 3.9 g | 4 weeks | 12 |
| A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial 2024 · experimental formula · Adults aged 55–85 with sarcopenia | 500 mg | 120 days | 30 |
| Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study 2025 · sodium butyrate group · Adults with MASLD and cardiometabolic risk criteria | 1 g | 12 weeks | 121 |
| Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study 2025 · calcium butyrate group · Adults with MASLD and cardiometabolic risk criteria | 1 g | 12 weeks | 60 |
| Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease 2020 · butyrose (BLM) treatment group · Adults over 18 with histologically confirmed Crohn's disease or ulcerative colitis | 1.8 g | 60 days | 21 |
| A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease 2013 · 50 mg/kg HQK-1001 · People with hemoglobin SS or S/β(0) thalassemia | 50 mg/kg | 26 weeks | 19 |
| A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease 2013 · 40 mg/kg HQK-1001 · People with hemoglobin SS or S/β(0) thalassemia | 40 mg/kg | 26 weeks | 18 |
| Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial 2024 · sodium-butyrate group · Adults aged 18–60 with mild to moderate active ulcerative colitis | 600 mg | 12 weeks | 18 |
| A Sustained-Release Butyrate Tablet Suppresses Ex Vivo T Helper Cell Activation of Osteoarthritis Patients in a Double-Blind Placebo-Controlled Randomized Trial 2024 · sustained-release butyrate tablet group · Adults aged 50–74 years with hand osteoarthritis | 600 mg | 4 weeks | 16 |
| A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease 2013 · 30 mg/kg HQK-1001 · People with hemoglobin SS or S/β(0) thalassemia | 30 mg/kg | 26 weeks | 15 |
| The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans 2015 · 200 g carrots + 6.53 g tributyrin · Healthy white men, mean age 24 years, mean BMI 22 | 6.53 g | 1 day | 12 |
| Infusion of donor feces affects the gut-brain axis in humans with metabolic syndrome 2020 · butyrate group · Men or post-menopausal women aged 50–70 years with metabolic syndrome | 4 g | 4 weeks | 12 |
| Butyrate esterified to starch is released in the human gastrointestinal tract 2011 · HAMSB20 · 16 volunteers; age, sex, and health condition not specified | 31.8 mmol | 2 weeks | — |
| Butyrate esterified to starch is released in the human gastrointestinal tract 2011 · HAMSB40 · 16 volunteers; age, sex, and health condition not specified | 40 g | 2 weeks | — |
| Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial 2020 · group A · People with type 2 diabetes; age and sex not reported | 600 mg | 45 days | — |
| Expression of PGC-1α, PPAR-α and UCP1 genes, metabolic and anthropometric factors in response to sodium butyrate supplementation in patients with obesity: a triple-blind, randomized placebo-controlled clinical trial 2025 · NaB group · People with obesity | 600 mg | 8 weeks | — |
| Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial 2024 · Active treatment · Adults with ultrasound-diagnosed liver steatosis and metabolic syndrome | 1 g | 12 weeks | 25 |
| Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial 2020 · group C · People with type 2 diabetes; age and sex not reported | 600 mg | 45 days | — |